Patents by Inventor Shaopei CHEN

Shaopei CHEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • High affinity cell receptor for recognizing AFP antigen
    Patent number: 12275773
    Abstract: Provided in the present invention is a T cell receptor (TCR) having the property of binding to a FMNKFIYEI-HLA A0201 complex; and the binding affinity of the TCR to the FMNKFIYEI-HLA A0201 complex is at least 2 times the binding affinity of the wild-type TCR to the FMNKFIYEI-HLA A0201 complex. Also provided in the present invention is a fusion molecule of such TCRs with therapeutic agents. Such TCRs can be used alone or in combination with therapeutic agents, so as to target tumor cells presenting the FMNKFIYEI-HLA A0201 complex.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: April 15, 2025
    Assignee: XLIFESC, LTD.
    Inventors: Yi Li, Xiaolin Li, Shaopei Chen
  • TCR CAPABLE OF RECOGNIZING HPV ANTIGEN
    Publication number: 20240002464
    Abstract: The present invention provides a T cell receptor (TCR) capable of specifically binding to HPV 16 E6 antigen short peptide complex TIHDIILECV-HLA A0201. Moreover, an effector cell transducing the TCR of the present disclosure also has a strong killing function. Such TCR can be used separately or in combination with other therapeutic agents, and can also be used in adoptive cellular immunotherapy to target a tumor cell presenting the complex TIHDIILECV-HLA A0201.
    Type: Application
    Filed: November 23, 2021
    Publication date: January 4, 2024
    Inventors: Yi LI, Dongxue YANG, Shaopei CHEN, Hanli SUN
  • HIGH-AFFINITY TCR FOR RECOGNIZING SSX2 ANTIGEN
    Publication number: 20220315639
    Abstract: Provided is a T-cell receptor (TCR) having the characteristic of binding to a KASEKIFYV-HLA A0201 complex, wherein the binding affinity of the TCR to the KASEKIFYV-HLA A0201 complex is at least two times that of a wild-type TCR to the KASEKIFYV-HLA A0201 complex. The TCR may be used alone or in combination with a therapeutic agent, so as to target tumor cells presenting the KASEKIFYV-HLA A0201 complex.
    Type: Application
    Filed: August 21, 2020
    Publication date: October 6, 2022
    Inventors: Shaopei CHEN, Hanli SUN
  • HIGH AFFINITY CELL RECEPTOR FOR RECOGNIZING AFP ANTIGEN
    Publication number: 20220033458
    Abstract: Provided in the present invention is a T cell receptor (TCR) having the property of binding to a FMNKFIYEI-HLA A0201 complex; and the binding affinity of the TCR to the FMNKFIYEI-HLA A0201 complex is at least 2 times the binding affinity of the wild-type TCR to the FMNKFIYEI-HLA A0201 complex. Also provided in the present invention is a fusion molecule of such TCRs with therapeutic agents. Such TCRs can be used alone or in combination with therapeutic agents, so as to target tumor cells presenting the FMNKFIYEI-HLA A0201 complex.
    Type: Application
    Filed: September 19, 2019
    Publication date: February 3, 2022
    Inventors: Yi LI, Xiaolin LI, Shaopei CHEN